An update on the current pharmacotherapy for endometrial cancer

被引：26

作者：

de Haydu, Christopher ^{[1
]}

Black, Jonathan D. ^{[2
]}

Schwab, Carlton L. ^{[2
]}

English, Diana P. ^{[2
]}

Santin, Alessandro D. ^{[2
]}

机构：

[1] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA

[2] Yale Univ, Sch Med, Gynecol Oncol Sect, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2016年 / 17卷 / 04期

关键词：

targeted therapy; endometrial cancer; chemotherapy; Adjuvant therapy; endometrial pharmacotherapy; hormone therapy; uterine cancer; PHASE-II TRIAL; PERFRINGENS ENTEROTOXIN CPE; DEPENDENT KINASE INHIBITOR; ENDOTHELIAL GROWTH-FACTOR; UTERINE SEROUS CARCINOMA; PTEN EXPRESSION; MEDROXYPROGESTERONE ACETATE; ADJUVANT CHEMOTHERAPY; AKT PHOSPHORYLATION; THERAPEUTIC TARGET;

D O I：

10.1517/14656566.2016.1127351

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Endometrial cancer (EC) is the most common gynecologic malignancy in the developed world and is increasing in incidence. While the mainstay of treatment for EC is surgery followed by chemotherapy and/or radiation therapy, the available pharmacotherapies are rapidly and constantly evolving. Understanding these new therapies is an important part of the research and clinical care of women with EC. A review of available literature from MEDLINE (1879-2015) was conducted for the historic treatments and current therapies available for endometrial tumors. Areas covered: This article reviews the current conventional therapies and discusses novel therapeutic agents, some of which are available to clinicians while others are currently being investigated in the preclinical setting. Expert opinion: Genomic and immunohistochemical characterization of endometrial cancer may soon be the best approach for the identification of aggressive forms of tumor. Targeted therapies will soon be standard in the management of endometrial cancer.

引用

页码：489 / 499

页数：11

共 148 条

[51] Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer [J].

Doldi, N ;

Bassan, M ;

Gulisano, M ;

Broccoli, V ;

Boncinelli, E ;

Ferrari, A .

GYNECOLOGICAL ENDOCRINOLOGY, 1996, 10 (06) :375-382

[52] Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway [J].

Dong, Peixin ;

Xu, Zhujie ;

Jia, Nan ;

Li, Dajin ;

Feng, Youji .

MOLECULAR CANCER, 2009, 8

[53] In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma [J].

El-Sahwi, K. ;

Bellone, S. ;

Cocco, E. ;

Cargnelutti, M. ;

Casagrande, F. ;

Bellone, M. ;

Abu-Khalaf, M. ;

Buza, N. ;

Tavassoli, F. A. ;

Hui, P. ;

Silasi, D-A ;

Azodi, M. ;

Schwartz, P. E. ;

Rutherford, T. J. ;

Pecorelli, S. ;

Santin, A. D. .

BRITISH JOURNAL OF CANCER, 2010, 102 (01) :134-143

[54] Focus on endometrial and cervical cancer [J].

Ellenson, LH ;

Wu, TC .

CANCER CELL, 2004, 5 (06) :533-538

[55] Hormonal interactions in endometrial cancer [J].

Emons, G ;

Fleckenstein, G ;

Hinney, B ;

Huschmand, A ;

Heyl, W .

[56] Claudins Overexpression in Ovarian Cancer: Potential Targets for Clostridium Perfringens Enterotoxin (CPE) Based Diagnosis and Therapy [J].

English, Diana P. ;

Santin, Alessandro D. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (05) :10412-10437

[57] Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients [J].

Fabre, Claire ;

Gobbi, Marco ;

Ezzili, Cyrine ;

Zoubir, Mustapha ;

Sablin, Marie-Paule ;

Small, Karen ;

Im, Ellie ;

Shinwari, Nabeegha ;

Zhang, Da ;

Zhou, Honghong ;

Le Tourneau, Christophe .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) :1057-1064

[58] The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study [J].

Finn, Richard S. ;

Crown, John P. ;

Lang, Istvan ;

Boer, Katalin ;

Bondarenko, Igor M. ;

Kulyk, Sergey O. ;

Ettl, Johannes ;

Patel, Ravindranath ;

Pinter, Tamas ;

Schmidt, Marcus ;

Shparyk, Yaroslav ;

Thummala, Anu R. ;

Voytko, Nataliya L. ;

Fowst, Camilla ;

Huang, Xin ;

Kim, Sindy T. ;

Randolph, Sophia ;

Slamon, Dennis J. .

LANCET ONCOLOGY, 2015, 16 (01) :25-35

[59] Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A gynecologic oncology group study [J].

Fleming, GF ;

Brurietto, VL ;

Cella, D ;

Look, KY ;

Reid, GCH ;

Munkarah, AR ;

Kline, R ;

Burger, RA ;

Goodman, A ;

Burks, RT .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2159-2166

[60] Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study [J].

Fleming, Gini F. ;

Filiaci, Virginia L. ;

Marzullo, Brandon ;

Zaino, Richard J. ;

Davidson, Susan A. ;

Pearl, Michael ;

Makker, Vicky ;

Burke, James J., II ;

Zweizig, Susan L. ;

Van Le, Linda ;

Hanjani, Parviz ;

Downey, Gordon ;

Walker, Joan L. ;

Reyes, Henry D. ;

Leslie, Kimberly K. .

GYNECOLOGIC ONCOLOGY, 2014, 132 (03) :585-592

← 1 2 3 4 5 6 7 8 9 10 →